Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 11/20 | 0.56 |
| ▸ | JAK1 | P23458 | 8/20 | 0.56 |
| ▸ | JAK2 | O60674 | 8/20 | 0.56 |
| ▸ | STAT6 | P42226 | 4/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913215 | 0.87 | STAT6 (0.58) | JAK3JAK1JAK2STAT6NTRK1 | |
| SCHEMBL12904875 | 0.86 | STAT6 (0.56) | JAK3JAK1JAK2STAT6NTRK1 | |
| SCHEMBL914711 | 0.83 | STAT6 (0.56) | JAK3JAK1JAK2STAT6NTRK1 | |
| SCHEMBL914215 | 0.82 | JAK3 (0.68) | JAK3JAK1JAK2STAT6NTRK1 | |
| SCHEMBL942933 | 0.79 | SYK (0.55) | JAK3JAK1STAT6TYK2EGFR | |
| SCHEMBL914015 | 0.79 | STAT6 (0.59) | JAK3JAK1JAK2STAT6 | |
| SCHEMBL913546 | 0.79 | STAT6 (0.62) | JAK3JAK1JAK2STAT6PTK2 | |
| SCHEMBL913086 | 0.78 | JAK3 (0.64) | JAK3JAK1JAK2STAT6NTRK1 | |
| SCHEMBL12904935 | 0.78 | JAK3 (0.66) | JAK3JAK1JAK2STAT6NTRK1 | |
| SCHEMBL913659 | 0.78 | SYK (0.56) | JAK3JAK1JAK2TYK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | claimed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | claimed |
| EP-2602255-B1 | FUSED HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-26 | — | — | EP | disclosed |
| EP-2604597-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF INHIBITOR OF PHOSPHODIESTERASE 10A | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9150588-B2 | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-8883788-B2 | Fused heterocyclic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2604597-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-2602255-A1 | FUSED HETEROCYCLIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2010129802-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129802-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | JAK3 3/4885JAK1 1/4885JAK2 2/4885 |
| US-20110005947-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | JAK3 3/4885JAK1 1/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.